Duramed Cenestin
Executive Summary
Composition patent for Cenestin (synthetic conjugated estrogens, A) tablets granted June 1. The "pharmaceutical compositions of conjugated estrogens and methods for their use" patent (5,908,638) provides market exclusivity to Duramed until July 26, 2015. FDA approved the product for the treatment of impaired vasomotor symptoms associated with menopause March 24